Kestra Medical Technologies (NASDAQ:KMTS) has announced a strategic collaboration and exclusive co-development agreement with Biobeat Technologies to integrate advanced hemodynamic monitoring into its cardiac recovery platform.
The partnership will bring Biobeat’s FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring (ABPM) technology into Kestra’s ASSURE Wearable Cardioverter Defibrillator (WCD) ecosystem.
As part of the agreement, Kestra has made a $5 million equity investment in Biobeat’s Series B financing round.
The move aims to provide clinicians with continuous, non-invasive blood pressure data, addressing a critical gap in at-home patient management during the high-risk period following a cardiac event.
The clinical necessity of the partnership is underscored by Kestra’s recent ACE-PAS study, the largest real-world evaluation of WCDs to date.
The study revealed that 72% of patients using the ASSURE system were hypertensive, highlighting a widespread need for better visibility into blood pressure trends to optimize guideline-directed medical therapy.
"Health care providers have consistently told us that better visibility to blood pressures during cardiac recovery would meaningfully support clinical decision making," said Brian Webster, President and CEO of Kestra.
By embedding Biobeat's patch-worn sensor technology, the ASSURE system will transition from a reactive life-saving device to a proactive diagnostic tool, allowing care teams to manage complex cardiac patients with greater precision.